BMI View: Taiwan is one of the most attractive and stable prospects in the region for pharmaceutical and
healthcare investment, but is not without flaws. Weaknesses in the country's regulatory regime and drug
pricing concerns will continue to deter multinational interest over o ..."
BMI View: BMI believes that cost-containment policies will not place significant pressure on healthcare
expenditure in Taiwan. This is because the majority of spending in the medical services sector goes towards
salaries for doctors and nurses, which are difficult to ..."
BMI View: On the back of the rising aged dependency ratio, demands for long-term care and welfare
expenditure are expected to rise in Taiwan, adding further weight on the government's fiscal burden. In this
respect, we particularly highlight the rising importance of e ..."
BMI View: Taiwan's ageing population continues to be a key driver of pharmaceutical sales in the country.
However, while the increase in premium collection resulted in a strong balance sheet for the National
Health Insurance (NHI) scheme, it runs a risk of returning t ..."
GBI Research, the leading business intelligence provider, has released its latest research "Taiwan Pharmaceutical Market Outlook 2013". The report focuses on the Taiwanese pharmaceutical market, providing market analysis and a forecast to 2018. It prov ..."
BMI View: Taiwan will continue to represent a modestly attractive proposition for drug manufactures. Our
view is based on factors such as the maturity of its pharmaceutical market, government encouragement of
generic medicines and authorities desire to reduce unnecessary use of ..."
BMI View: We continue viewing Taiwan as a relatively mature pharmaceutical market. As such, we forecast a compound annual growth rate (CAGR) of 3.5% in local currency terms and 5.2% in US dollar terms through to 2017, by which point per capita expenditure on medicines is expected ..."
We continue to view Taiwan as a challenging market for multinationals, mostly on account of the difficult pricing and reimbursement environment, which is due to undergo further changes. Specifically, as part of the Second Generation National Health Insurance (NHI) programme, whic ..."
BMI View: We continue to view Taiwan as a challenging market for multinationals, mostly on account of
the difficult pricing and reimbursement environment, which is due to undergo further changes.
Specifically, as part of the Second Generation National Health Insurance (NHI) pro ..."